What are brokers saying about CSL shares after the selloff?

The biotech giant's shares hit a 52-week low yesterday. Is this a buying opportunity?

| More on:
thoughtful investor sitting at computer

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Ltd (ASX: CSL) shares were under pressure on Tuesday.

Despite initially charging higher following the release of its half year results, the biotechnology giant's shares ultimately ended the session with a 5% decline to $256.96.

While this was disappointing, has it created a buying opportunity? Let's see what two leading brokers are saying.

Are CSL shares a top buy?

With its shares hitting a 52-week low yesterday, both Bell Potter and Goldman Sachs think investors should be jumping on them while they are down in the dumps.

According to a note out of Bell Potter, its analysts have retained their buy rating with a trimmed price target of $335.00 (from $345.00).

Based on its current share price, this implies potential upside of 30% for investors over the next 12 months.

Commenting on its results, the broker said:

Revenue was up +5% but 1% below BPe and VA consensus. NPATA was up +3% to $2.07b but 4% below BPe and VA consensus. The miss at revenue was driven by Seqirus underperformance (-8% on pcp), partially offset by Vifor outperformance (+7%), while Behring (+10%) was in-line.

Bell Potter thinks investors should look beyond Seqirus' poor performance and focus on the improving performance of the key CSL Behring business. It said:

We have lowered our PT to $335 (from $345) but maintain our BUY recommendation. While the declining US flu market has caused headwinds for Seqirus, Behring continues its strong growth outlook and positive margin recovery, which we expect will continue to drive double digit earnings growth for the group over the mid-term.

Goldman remains bullish

A note out of Goldman Sachs reveals that its analysts have retained their buy rating on CSL's shares with a trimmed price target of $318.40. This suggests that upside of 24% is possible for investors from current levels.

Goldman shares a similar view as Bell Potter. It said:

Whilst the miss to CSL Seqirus (-10% vs GSe) was disappointing, we note this segment is navigating challenging market conditions reflected by peers Sanofi and GSK reporting revenue declines of -6% to -15% across the corresponding half. With market share gains unlikely to feature as a lever for growth across the near term, we reduce FY26/27 Seqirus revenue forecasts by -12%.

Ultimately, CSL Behring (68% of group FY25 Gross Profit) remains the key earnings driver for the group and the result reinforced the earnings drivers for this segment are intact.

The broker also highlights that it believes CSL can still deliver on its earnings guidance for FY 2025. It concludes:

With ongoing momentum in IG sales and other products of the CSL's portfolio partially offsetting the weakness to Seqirus, we believe the company is well-placed to deliver on FY25 NPATA guidance (GSe: +12% CC NPATA). Reiterate Buy recommendation.

Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Goldman Sachs Group. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a young woman holds her hand to her ear and leans sideways as if to listen to something that's surprising her as her eyes and her mouth are wide open.
Healthcare Shares

Down 15% since January, are Cochlear shares now a buy?

Let's see what analysts are saying about this blue chip.

Read more »

Green arrow with green stock prices symbolising a rising share price.
Healthcare Shares

Guess which popular ASX 200 stock is up nearly 60% in less than 2 months?

Investors who bought this ASX 200 stock in the recent dip have been strongly rewarded.

Read more »

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

Are Sigma Healthcare shares a good buy now after the merger with Chemist Warehouse?

Sigma Healthcare shares have soared 154% in 12 months. Can this stellar run continue?

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Up 34% since April, ASX 300 healthcare stock lifts off again today on new milestone

The ASX 300 healthcare stock has been on a tear since hitting one-year lows in April.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »

A woman relaxes on a yellow couch with a book and cuppa, and looks pensively away as she contemplates the joy of earning passive income.
Healthcare Shares

NIB shares have soared 24% this year. Does Macquarie expect this to continue?

Will this private health insurer continue to deliver big returns? Let's find out.

Read more »

Woman presenting financial report on large screen in conference room.
Healthcare Shares

Up nearly 30% in a year, should I buy Fisher & Paykel shares before its earnings result?

Will the ASX 200 healthcare stock continue to outperform?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL shares among most expensive on ASX. Is now a good time to buy?

Analysts predict CSL share price growth will keep on coming.

Read more »